Helix BioPharma Reports Financial Loss, Seeks Funding Amid Cash Crunch

Helix BioPharma Reports Financial Loss, Seeks Funding Amid Cash Crunch

Key Takeaways (TLDR)

  • Helix BioPharma’s pursuit of U.S. exchange listing and new financing could offer investors early entry into a clinical-stage oncology company targeting hard-to-treat cancers.
  • Helix BioPharma reported reduced losses due to completed trials but faces cash shortages, with active financing efforts including a new term sheet after a failed subscription agreement.
  • Helix BioPharma’s oncology pipeline aims to make today’s hardest-to-treat cancers vincible, potentially improving future cancer treatment options and patient outcomes.
  • Helix BioPharma’s L-DOS47 targets CEACAM6-expressing tumors to boost therapy sensitivity, while its pipeline includes novel oral treatments for leukemia and advanced cancers.

Why it Matters

This news matters because Helix BioPharma’s financial struggles highlight the precarious nature of small-cap biotech companies, especially in oncology where research costs are high and timelines are long. For investors, the company’s cash position and failed financing deal with Quantum Global Ventures AG signal significant risk, potentially affecting stock performance and future viability. For patients, Helix’s pipeline—including L-DOS47 for tumors like non-small cell lung cancer—represents potential advancements in cancer treatment, but its development hinges on securing funding. The broader biotech sector may see ripple effects, as such challenges can impact investor confidence in early-stage medical innovations, underscoring the importance of stable financing for bringing new therapies to market.

Summary

Helix BioPharma Corp., a clinical-stage oncology company trading on the TSX (HBP), OTC PINK (HBPCD), and Frankfurt (HBP0) exchanges, has released its unaudited interim financial statements for the three- and six-month periods ending January 31, 2026. The company, led by CEO Thomas Mehrling, MD, PhD, reported a net loss of $694,000 for the quarter and $1,702,000 for the six-month period, showing a decrease from the previous year primarily due to the conclusion of its LDOS006 clinical trial in metastatic pancreatic adenocarcinoma. Despite these losses, the company’s core focus remains on securing financing to advance its oncology pipeline, which includes the clinical-stage Tumor Defense Breaker™ L-DOS47 for CEACAM6-expressing tumors, as well as pre-IND candidates LEUMUNA™ and GEMCEDA™.

The financial position reveals significant challenges, with cash reserves plummeting to just $31,000 as of January 31, 2026, down from nearly $2 million a year earlier. This stark decline underscores the company’s urgent need for capital, as existing funds are insufficient to support operations through the next twelve months. A major setback occurred when a $33.4 million financing deal with Quantum Global Ventures AG collapsed after the investor declared bankruptcy, leaving Helix without the anticipated proceeds. In response, the company has since signed a term sheet with Alumni Capital Limited for a potential new financing transaction, though specific terms remain confidential under the company’s obligations.

Helix BioPharma’s interim filings, which include the financial statements, management’s discussion and analysis (MD&A), and CEO/CFO certifications, are available for review on the company’s profile at www.sedarplus.ca and on its website. The company emphasizes its commitment to developing near-term solutions for hard-to-treat cancers, leveraging its innovative pipeline to potentially enhance the effectiveness of existing anti-cancer treatments. As Helix navigates a difficult capital markets environment, its ability to secure financing will be critical for advancing its research and development activities, including the pursuit of a U.S. securities exchange listing, which remains a key near-term objective for the company’s future growth and sustainability.

Blockchain Registration, Verification & Enhancement provided by NewsRamp™

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Helix BioPharma Reports Financial Loss, Seeks Funding Amid Cash Crunch.

Author

  • George Griffin

    Providing consultant services relating to the overseeing of General Accounting and Financial Reporting functions and various financial services including A/R, A/P, Payroll, Property Control, and Compliance.. Responsibilities include implementing and maintaining a system of internal controls that will ensure that company assets are properly safeguarded and that all financial reporting is prepared in compliance with internal financial policies, SEC requirements and US GAAP. Coordinate and oversee the Sarbanes Oxley activities relative to internal controls documentation and testing to ensure proper segregation of duties. Strong background in setup, implementation and operation of Deltek Costpoint and JAMIS softwares used for government cost accounting. Providing technical accounting and cost accounting compliance guidance for companies working for the Federal Government.

Artículos relacionadosMás del autor